Literature DB >> 3501404

Immunoglobulin G-binding factors (IgG-BF) inhibit IgG secretion by, as well as proliferation of, hybridoma B cells.

J L Teillaud1, S Amigorena, J Moncuit, C Sautès, W H Fridman.   

Abstract

Mouse immunoglobulin G-binding factors (IgG-BF) produced either by activated T cells (ATC) or by hybridoma T cells (T2D4) directly inhibit the in vitro IgG secretion by hybridoma B cells. This inhibition affects IgG1, IgG2a and IgG2b and can be detected as early as after 2 h incubation of the cells with IgG-BF eluted from non-equilibrium pH gradient electrophoresis gels. Moreover, IgG-BF also exert a strong growth-inhibitory effect on hybridoma B cells without any detectable immediate cytotoxicity. These results provide an experimental basis to analyze the molecular and biological effects induced by IgG-BF on B cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3501404     DOI: 10.1016/0165-2478(87)90121-0

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  5 in total

1.  In vitro inhibition of tumor B cell growth by IgG-BF-producing Fc gamma RII+ T cell hybridoma and by immunoglobulin G-binding factors.

Authors:  C Mathiot; S Amigorena; J Moncuit; C Sautès; W H Fridman; J L Teillaud
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

2.  Prognostic significance of the heterogenous expression of IgG Fc receptors in B-cell chronic lymphocytic leukemia.

Authors:  V Schranz; F Gráf
Journal:  Ann Hematol       Date:  1992-03       Impact factor: 3.673

Review 3.  The biology and pathology of Fc receptors.

Authors:  M Sandor; R G Lynch
Journal:  J Clin Immunol       Date:  1993-07       Impact factor: 8.317

4.  Increased levels of soluble low-affinity Fc gamma receptors (IgG-binding factors) in the sera of tumour-bearing mice.

Authors:  A Lynch; E Tartour; J L Teillaud; B Asselain; W H Fridman; C Sautès
Journal:  Clin Exp Immunol       Date:  1992-02       Impact factor: 4.330

5.  Correlation between soluble serum CD16 (sCD16) levels and disease stage in patients with multiple myeloma.

Authors:  C Mathiot; J L Teillaud; M Elmalek; V Mosseri; L Euller-Ziegler; A Daragon; B Grosbois; J L Michaux; T Facon; J F Bernard
Journal:  J Clin Immunol       Date:  1993-01       Impact factor: 8.317

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.